aortic stenosis

EuroPCR 2023 | Intravascular Lithotripsy (IVL) Balloon in the Treatment of Underexpanded Stents

Calcified coronary plaque (CCP) is a challenge for interventional cardiology. Stent underexpansion (SU) commonly associated with CCP could predispose to stent thrombosis or restenosis. Currently, SU in severe CCP can be treated by rotational atherectomy, orbital atherectomy, balloon cutting/scoring, non-compliant high-pressure balloons, or intravascular lithotripsy (IVL). The aim of this meta-analysis was to determine the<a href="https://solaci.org/en/2023/05/22/europcr-2023-intravascular-lithotripsy-ivl-balloon-in-the-treatment-of-underexpanded-stents/" title="Read more" >...</a>

La angina microvascular podría tener gradientes de riesgo

Post PCI Angina: Inevitable or Avoidable?

Predictors of post PCI angina&nbsp; Among the complications of ischemic cardiomyopathy stenting, those called chronic, with significant functional and mental compromise, might affect patient quality of life. This can be observed in different scenarios, such as instent restenosis and post PCI angina. This kind of complications is associated with anxiety and depression at long term.&nbsp;<a href="https://solaci.org/en/2023/05/09/post-pci-angina-inevitable-or-avoidable/" title="Read more" >...</a>

TAVI bajo riesgo

Evolute Low Risk at 3 Years: Promising Outcomes

Transcatheter aortic valve replacement has shown important benefits but one of its biggest challenges is showing its safety and efficacy at followup in low risk patients. At present we have 2-year data from the Evolute Low Risk, but the we lack information at longer followup.&nbsp; The study looked at 3-year followup of the Evolute Low<a href="https://solaci.org/en/2023/05/03/evolute-low-risk-at-3-years-promising-outcomes/" title="Read more" >...</a>

The most read scientific articles in interventional cardiology in February on our website

Below, we share February&#8217;s most read scientific abstracts in interventional cardiology at solaci.org. Can Drug Coated Balloon Be a Valid Option for Small Vessels? One of the challenges of percutaneous coronary interventions (PCI) are &lt;2.5 mm vessels, since complications and restenosis complications rate are higher than with &gt;3.0 mm vessels.&nbsp;&nbsp; Is Using Drug-Eluting Balloons and<a href="https://solaci.org/en/2023/03/22/the-most-read-scientific-articles-in-interventional-cardiology-in-february-on-our-website/" title="Read more" >...</a>

ACC 2023 | TAVR in Low Risk Patients: 3-Year Outcomes

At present, transcatheter aortic valve replacement (TAVR) has become the gold standard in the US, regardless surgical risk. The current ACC and AHA guidelines recommend that a Heart Team make the decision for 65 to 80-year-old patients with aortic stenosis.&nbsp; In low risk patients, fast recovery and short term benefits of TAVR should be weighed<a href="https://solaci.org/en/2023/03/08/acc-2023-tavr-in-low-risk-patients-3-year-outcomes/" title="Read more" >...</a>

Síndrome de Tokotsubo ¿El género tiene influencia en su pronóstico?

Plaque Erosion with No Stenting in Acute Coronary Syndrome: Are There Event Predictors to Avoid This Strategy?

&nbsp;Event predictors in patients with plaque erosion and no stenting. A third of all acute coronary syndrome (ACS) cases are caused by plaque erosion. In the initial EROSION study, it was shown that patients with plaque erosion (as evidenced by OCT, with stenosis &lt;70%, TIMI III flow, and asymptomatic) were stabilized without stent implantation (no<a href="https://solaci.org/en/2023/02/13/plaque-erosion-with-no-stenting-in-acute-coronary-syndrome-are-there-event-predictors-to-avoid-this-strategy/" title="Read more" >...</a>

FRAME-AMI: FFR vs. Angiography of Non-Culprit Vessel in ACS

This study compared fractional flow reserve (FFR) vs. angiography to guide the angioplasty of non-culprit vessels in patients with acute coronary syndrome (ACS) and multivessel disease. Landmark studies such as COMPLETE, COMPARE-ACUTE and DANAMI-3-PRIMULTI have demonstrated the prognostic value of revascularization (after treatment of the artery responsible for the ACS) of non-culprit arteries with respect<a href="https://solaci.org/en/2023/01/25/frame-ami-ffr-vs-angiography-of-non-culprit-vessel-in-acs/" title="Read more" >...</a>

Nueva y discrepante información sobre los vasos no culpables en el infarto

Non-ST Elevation MI: How Long Do We Have for A Coronary Angiography?

This summary discusses the early invasive strategy and the risk of mortality in non-ST-elevation AMI. Over the past 2 decades, mortality and complications rates have seen a significant reduction thanks to technological and pharmaceutical development, and the increasing experience of health teams. This is especially true when we look at the use of coronary angiography<a href="https://solaci.org/en/2023/01/20/non-st-elevation-mi-how-long-do-we-have-for-a-coronary-angiography/" title="Read more" >...</a>

intervencion percutanea

Intervention in Patients with Takayasu Arteritis: Rescue Therapy or an Alternative Complementary to Immunosuppressive Therapy?

Takayasu arteritis (TAK) is an uncommon granulomatous large-vessel vasculitis that affects the aorta and its primary branches. The most frequently types of observed vascular compromise are obstructive lesions, and aneurysmal vascular lesions or dissections. In 2021, the American College of Rheumatology recommended not to implement percutaneous intervention (PI) with these patients and only use immunosuppressive<a href="https://solaci.org/en/2023/01/18/intervention-in-patients-with-takayasu-arteritis-rescue-therapy-or-an-alternative-complementary-to-immunosuppressive-therapy/" title="Read more" >...</a>

The most read articles in interventional cardiology

Interventional cardiology: the most read articles of 2022 in solaci.org

Discover the most read scientific articles on interventional cardiology of 2022 in our website. The FDA Approves Intravascular Lithotripsy for Calcified Lesions The&nbsp;US&nbsp;Food and Drug Administration&nbsp;(FDA)&nbsp;has cleared the shockwave lithotripsy system to treat severely calcified plaque lesions. Is Epinephrine Superior to Adenosine in No-REFLOW? In patients with&nbsp;acute coronary syndrome,&nbsp;no-reflow&nbsp;prevalence is&nbsp;32%. Different drugs—such as adenosine, verapamil,<a href="https://solaci.org/en/2023/01/05/interventional-cardiology-the-most-read-articles-of-2022-in-solaci-org/" title="Read more" >...</a>

Top